World Congress Insulin Resistance Diabetes & Cardiovascular Disease November 20-22, 2014

World Congress Insulin Resistance
Diabetes & Cardiovascular Disease
’s
w
o
r
r
mo
o
T
m
bolis
a
t
e
M
n
i
Exploring New Frontiers
November 20-22, 2014
Hilton, Universal City
Los Angeles, California
JOINTLY SPONSORED:
PESI INC.
Metabolic Endocrine
Education Foundation
CO-SPONSORS:
AMERICAN ASSOCIATION OF
CLINICAL ENDOCRINOLOGISTS
AMERICAN COLLEGE
OF ENDOCRINOLOGY
Administered by Metabolic Institute of America
ay
d
o
eT
c
n
cie
S
l
ca
i
n
i
l
C
sulin
ess on In ears
r
g
n
o
C
y
orld
Annual W ce its inception 12 betes,
h
t
2
1
e
r th
. Sin
y, dia
join us fo ease (WCIRDC) edicated to obesit for clinical
:
e
o
u
t
g
u
a
e
o
y
ll
Dear Co leasure to invite ardiovascular Dis global meeting d lusive opportunity emerging
It is my p e, Diabetes, and Come the premiere It provides an exc o collaborate on
Resistanc Congress has bec d energy balance. ticing clinicians t
experts
l
a
b
n
c
e
lo
a
a
h
g
r
,
t
p
m
,
d
s
e
d
ago D, metaboli
s.
distinguish
tice. This
rchers, an
lipids, CV scientists, resea nagement strategie, with a faculty of ch to clinical pracal Science
and basic principles and ma f-the-art program ach linking resear omorrow's Clinic
scientific IRDC is a state-o to-bedside appro rs in Metabolism-T
of
recipient lph
e
h
t
i,
in
The WC g a unique bench- ring New Frontie
n
rran
y Ra
or Ele Fe posium chaired b mongst
s
s
e
presentin s our theme "Explo
f
o
r
P
a
de
sym
gram incluce” Award, and a Additional symposia haired by
highlight
o
r
p
's
r
a
e
Today. hlights from this y in Insulin Resistan ose Homeostasis. tabolic Health- C
Some hig inguished Leader e Kidney in Gluc weeteners and Me m.
, Ronald
g
r
t
h
e
S
a
t
r
is
b
s
g
f
ic
D
r
o
o
"
in
r
lo
p
e
G
le
th
d Non-Ca
t, Henry
nd a Lipid
oith, John
o: The Ro
DeFronz ers are: Caloric an VD in Diabetes, a aven, Peter Gran tzky, Derek LeR join us for
many oth lein, CHF and C cludes Gerald Re onseca, Jorge Plu ard to having you
Samuel K brated faculty in t Staels, Vivian F a few. I look forw
The cele obert Henry, Bar oros, to name just
Krauss, R nd Christos Mantz s Angeles.
Nestler, a ing program in Lo
this excit
rds,
Best rega
MD
ndelsman tor
a
H
a
d
u
h
Ye
ram Direc
g
o
r
P
&
Chair
Scientific Organizing Committee - International Committee for Insulin Resistance - ICIR
Yehuda Handelsman, MD CHAIR
Tarzana, California
Samuel W. Cushman, PhD
Bethesda, Maryland
Peter J. Grant, MD
Leeds, United Kingdom
Nikolaus Marx, MD
Aachen, Germany
Zachary T. Bloomgarden, MD
New York, New York
Jaime A. Davidson, MD
Dallas, Texas
Paul S. Jellinger, MD
Hollywood, Florida
Tracey L. McLaughlin, MD
Stanford, California
Sonia Caprio, MD
New Haven, Connecticut
Ralph DeFronzo, MD
San Antonio, Texas
Samuel Klein, MD
St Louis, Missouri
Jorge Plutzky, MD
Boston, Massachusetts
Robert J. Chilton, DO
San Antonio, Texas
Daniel Einhorn, MD
La Jolla, California
Ronald Krauss, MD
Berkeley, California
Alan R. Sinaiko, MD
Minneapolis, MN
Rhoda Cobin, MD
Midland Park, New Jersey
W. Timothy Garvey, MD
Birmingham, Alabama
Philip Levy, MD
Phoenix, Arizona
Bart Staels, PhD
Lille France
Program Description
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 12th year, is a unique and exciting multidisciplinary program, to be held this
year in Universal City, California. The Congress is the premiere global meeting dedicated to diabetes, obesity, metabolism, and energy balance, linking research to clinical
practice, and highlighting our theme — Exploring New Frontiers in Metabolism — Tomorrow's Clinical Science Today.
Since its inception, the Congress has become a home to clinical & basic scientists, researchers, and practicing clinicians. The distinguished global faculty, employing the Congress’
unique bench-to-bedside approach, has created a state-of-the-art program, promoting a new understanding of metabolic diseases; facilitating the development of future
therapeutic modalities; and implementing the management of obesity and diabetes beyond lifestyle, with contemporary medications and surgeries.
Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, and cardiovascular disease (CVD), the Congress’ focus has been
augmented by the role of obesity, fat cell, and inflammation, in furthering cardiometabolic conditions. The WCIRDC is a distinguished platform where the interaction of multiple
metabolic systems, like circadian rhythm, sleep disturbances, the neuroendocrine system, the gut, related hormones, and their relationship to the brain, are evaluated in both
the scientific and clinical environments. Ultimately the Congress is set on developing an innovative and comprehensive plan for managing CV risk factors and diseases.
Diabetes and obesity carry major risks for cardiovascular complications and for cancer. The epidemic of obesity propels the epidemic of diabetes. The obesity epidemic also
defines the components of the pathophysiology causing these complications — insulin resistance, endothelial dysfunction, lipid abnormalities, hypertension,
hyperglycemia, and hypercoagulation.
A comprehensive approach to understanding and managing these risk factors is mandatory in the prevention and treatment of complications of diabetes. Beyond lifestyle
modification, a focus on pharmacological agents is key to addressing the epidemic. Of particular interest is our contemporary understanding of the pathophysiology of diabetes,
incorporating the role of the kidney in glucose homeostasis and the role of the incretin system. This year, on top of the general scientific spectrum of the Congress, namely
addressing obesity, diabetes, cardiovascular disease, and their management, there will be a particular focus on congestive heart failure, peripheral vascular disease (PVD),
thrombosis, and the role of the kidney in energy balance and metabolism. Addressing new therapeutic modalities to allow clinical management of these conditions is a key
feature of the Congress.
For the primary care clinician, the Congress will also feature a series of workshops and “Meet The Expert” panels on the clinical management of diabetes, obesity, lipids, and
hypertension. To make basic and clinical research topics like brain metabolism, vascular biology, fat cells, inflammation, immunology, and the endothelium relevant to clinical
medicine, there will be clinical implications commentaries and panel discussions by recognized clinical experts following these sessions. The structure of the Congress promotes
personal and intimate contact between participants and the faculty.
The Congress attracts state-of-the-art abstracts from around the globe. These abstracts will be published in Endocrine Practice, the official journal of the American Association of
Clinical Endocrinologists (AACE). Typically, articles about the meeting are published in several medical journals, such as Endocrine Practice, The Journal of Diabetes, and Diabetes
Care.
Program Objectives
The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, and CVD, focusing on insulin resistance, hyperinsulinemia, fat cell, incretins,
the gut, the brain, the kidney and energy metabolism. The goal is to understand pathophysiology, and to develop appropriate comprehensive clinical management plans.
Upon completion of this meeting, participants should be able to:
• State the role of obesity in the development of cardiometabolic diseases, and its management based on a complications-centric model.
• Explain the roles of diabetes and insulin resistance in the development of kidney disease, retinopathy, and CVD.
• State how CHF as a consequence of diabetes, insulin resistance, and obesity, and understand contemporary management.
• Evaluate the extent of PVD and PAD in diabetes and obesity, and know their prevention and management modalities.
• Explain the role of the kidney in energy metabolism, in diabetes, and in the development of CVD.
• Discuss the role of the brain in energy balance and obesity.
• Explain hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes; and be aware of therapeutic agents.
• Discuss roles of inflammation and immunity in the effect of fat cells on the development of cardiometabolic conditions.
• Describe how to manage insulin resistance in diabetes with lifestyle, oral medications, and insulin.
• Explain the role of lipids, in particular low-density lipoproteins (LDL), in the development of atherosclerosis; and the role of medical societies’ guidelines in directing management.
• Discuss the role of incretins, in particular glucagon-like peptide-1 (GLP-1), in the management of obesity & diabetes and their complications.
• Describe the use sodium-glucose linked transporter 2 inhibitors (SGLT-2i) in the management of diabetes, and recognize their role in metabolism.
• Explain obesity's relation to food addiction, the role of taste receptors, hormonal response, and dopaminergic receptors.
• Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia.
• Describe polycystic ovary syndrome (PCOS) as a cardiometabolic condition.
• State the pathophysiology and complications of fatty liver disease.
• Evaluate the benefits and safety of anti-diabetic and obesity medications.
Target Audience
This educational initiative is designed for cardiologists, endocrinologists, gastroenterologists, oncologists, family physicians, internists, diabetologists,
OBGYNs, pediatricians, dieticians, nurse practitioners, pharmacists, and any other health care professional who is interested in insulin resistance, diabetes, obesity, and
cardiovascular disease, and multiple metabolic mechanisms' effect on health and society, as well as on potential treatment and prevention.
THURSDAY, NOVEMBER 20
7:00am
Registration • Continental Breakfast at Exhibit Hall
8:00am
Welcome & Introduction
Bart Staels, PhD
Yehuda Handelsman, MD / Chair
•
George Grunberger, MD / AACE President Elect
George Grunberger, MD
SESSION I
Chair:
8:15 am
Inflammatory, Thrombotic Interactions in Diabetes: The Road from Tissue Repair to Vascular Damage
8:45am
How Genetics Can and Will Improve Cardiometabolic Health
9:15am
Recent Advances in Management of Hepatic and Peripheral Insulin Resistance
9:45am-10:00am
Q + A & Panel Discussion Clinical Implications
10:00am-10:30am
SESSION II
Refreshment Break at Exhibit Hall
Chair: Samuel Cushman, MD
10:30am
Metabolic Effects of Overfeeding Humans
11:00 am
Effect of Calorie Restriction on Biological Function and Health
11:30am-11:40am
Q + A & Panel Discussion Clinical Implications
CONCURRENT SESSIONS
MEET THE EXPERTS
• Andrew Krentz, MD/Marcus Hompesch, MD
Measuring Insulin Action in Diabetes Drug Development
11:45am-12:35pm
Josh Knowles, MD, PhD
Robert Henry, MD
Tracey McLaughlin, MD
• Gerald M. Reaven, MD – Insulin Resistance
12:45pm – 1:45pm
Peter Grant, MD
PRODUCT THEATER
Samuel Klein, MD
• Ralph DeFronzo, MD - Insulin Resistance & Diabetes
• John Nestler, MD - PCOS
Non-CME
Advancing Paradigm Changes in Type 2 Diabetes Management
Lunch Will Be Served
Sponsored by: Janssen
George Grunberger, MD
Tracey McLaughlin, MD
•
Sonia Caprio, MD
SESSION III
Chair:
1:45pm
Systemic Insulin Resistance is Characterized by an Increased Fraction of Adipose Cells Refractive to Insulin
2:15pm
Insulin Resistance, Brain Dyslipidemia and Microvascular Injury: Recipe for Alzheimer's Disease
2:45pm
Relationships of Insulin Resistance, CVD Risk Factors, and Obstructive Sleep Apnea
3:15pm
Brain Response to Glucose Ingestion: Are Adolescents Different from Adults?
3:45pm-4:00pm
Q + A & Panel Discussion Clinical Implications
4:00pm-4:30pm
Refreshment Break At Exhibit Hall
Samuel Cushman, PhD
Suzanne Craft, PhD
Alice Liu, MD
Sonia Caprio, MD
THURSDAY, NOVEMBER, 20
Cont.
SESSION IV
Chair: Robert Chilton, DO
• Peter Grant, MD
4:30 pm
Late Breaking Research Non-CME : Exploring the Effect of Combination Treatment with
Lars Hansen, MD, PhD
Saxagliptin & Dapagliflozin on Glucagon Levels
SESSION V
Complexity of Peripheral Vascular Disease in the Insulin Resistant Patient: Bedside to Surgery
Chair: Robert Chilton, DO • Peter Grant, MD
4:50pm
Autonomic and Motor Neuropathy: Less Appreciated Aspects of the Diabetic Neuropathic Foot
5:10pm
Interaction of Vascular with Neuropathy in the Diabetes Foot: A Translational Look
5:30pm
Management Options in the Ischemic Diabetic Foot
5:50pm-6:00pm
Q + A & Panel Discussion Clinical Implications
Allen Jacobs, DPM
Lawrence Harkless, DPM
Mellick T. Sykes, MD
6:00 pm –7:00 pm
Poster Presentation, Receptions at the Exhibit Hall
CME SYMPOSIUM
Food Will Be Served
The Role of the Kidney in Glucose Homeostasis and Diabetes
Ralph DeFronzo, MD
Unexpected Metabolic Effects of SGLT2 Inhibition: An Update
Bart Staels, PhD
Contribution of the Kidney to Whole Body Glucose Homeostasis: A Critical Re-Evaluation
Ele Ferrannini, MD
Glucotoxicity: What Have SGLT2 Inhibitors Taught Us About Their Role in Beta Cell Dysfunction
& Insulin Resistance in T2DM?
Ralph DeFronzo, MD
SGLT2 Inhibitors and the Kidney: How Do They Really Work?
Muhammed Abdul-Ghani, MD, PhD
Q & A Panel Discussion - Clinical Impact of Whole Body Glucose Homeostasis
Moderator: Yehuda Handelsman, MD
Adjourn - Dessert Reception To Follow
Jointly Sponsored by: PESI & MEEF
Supported by : AstraZeneca
Chair:
7:00pm
7:20pm
7:55pm
8:25pm
8:55pm
9:30pm
FRIDAY, NOVEMBER, 21
Registration • Continental Breakfast at Exhibit Hall
Summary of First Day
7:00am
8:00am
SESSION VI
8:15am
8:45 am
9:15am
9:45am-10:00am
10:00am-10:30am
SESSION VII
10:30am
11:10am
11:40am
12:10pm-12:25pm
Zachary T. Bloomgarden, MD
The Heart, Insulin Resistance & Diabetes
Chair: Zachary T. Bloomgarden, MD • Jorge Plutzky, MD
New Diagnostic Tools to Detect Heart Disease in Diabetes
Cardiovascular Disease and Diabetes: Increasing Insulin Sensitivity and Changing the Phenotype
Is combination therapy still an option after the new AHA/ACC Guidelines
Q + A & Panel Discussion Clinical Implications
Robert Chilton, DO
Mark Kearney, MD
Henry Ginsberg, MD
Refreshment Break at Exhibit Hall
Fat, Obesity & Insulin Resistance
Chair: Ralph DeFronzo, MD • Rhoda Cobin, MD
Apple and Pear-Myth vs. Reality
Insulin Resistance-Lipodystrophy to Obesity
Proper Role of Metformin to Enhance Fertility in PCOS
Q + A & Panel Discussion Clinical Implications
CME SYMPOSIUM
Gerald Reaven, MD
W. Timothy Garvey, MD
John Nestler, MD
WCIRDC Attendees Are Entitled To A Complementary Lunch
Managing the High-Risk Patient, LDL & Beyond, Contemporary & Future Approaches
Welcome & Introduction
Yehuda Handelsman, MD Chair
Cardiovascular Disease and the High-Risk Person: Epidemiology, Pathophysiology,
Peter H. Jones, MD
Understanding Pathophysiology of Lipid Disorders, Focusing on the Role of PCSK9
in LDL-C Homeostasis
Christie M. Ballantyne, MD
Emergent Options for the Management of Lipid Disorders: Clinical Data from
Novel Classes of Drugs
Sergio Fazio, MD, PhD
Panel Discussion and Q&A: The Role of Treatment Goals and Medical Society Clinical Guidelines in
the Management of the High-Risk Patient
Adjourn
Jointly Sponsored by: PESI & MEEF
Supported by: Amgen
12:30pm
12:35pm
1:00pm
1:20pm
1:40pm
2:00pm
SESSION VIII
2:00pm
2:30pm
3:00pm
3:30pm-3:45pm
3:45pm-4:15pm
SESSION IX
4:15pm
4:45pm
5:15pm
5:45pm-6:00pm
6:00pm –7:30pm
Cardiometabolic, Atherosclerosis, Diabetes & Cancer
Chair: Alan Sinaiko, MD • W. Timothy Garvey, MD
Programmatic Control of Gene Expression Through Epigenetic Mechanisms: Inflammation and Atherosclerosis
Childhood Predictors of Adult Cardiometabolic Risk
Obesity, Diabetes & Cancer Risk
Q + A & Panel Discussion Clinical Implications
Refreshment Break At Exhibit Hall
Contemporary Issues in Lipid Disorders
Chair: Ronald Krauss, MD • Paul Jellinger, MD
Lp(a) in CVD and DM
Statin Intolerance: The Tip of the Iceberg?
Jekyll and Hyde of HDL: A Lipoprotein with a Split Personality
Q + A & Panel Discussion Clinical Implications
ABSTRACTS – ORAL PRESENTATIONS
Jorge Plutzky, MD
Olli Raitakari, MD, PhD
Derek LeRoith, MD, PhD
Sotirios Tsimikas, MD
Ronald Krauss, MD
Prediman Krishan (PK) Shah, MD
Refreshments Will Be Served
Zachary T. Bloomgarden, MD Chair • Philip Levy, MD • Daniel Einhorn, MD
Abstract are published in “Endocrine Practice” the official journal of the AACE | Editor-in-Chief: Derek LeRoith, MD, PhD
SATURDAY, NOVEMBER 22
7:00am
Registration • Continental Breakfast at Exhibit Hall
7:45am-7:55am
Oral Abstract Winners Presentation
7:55am-8:10am
Summary of Second Day
SESSION X
Caloric & Non-Caloric Sweeteners & Metabolic Health
Chair: Samuel Klein, MD
8:10am
Neurobiological Mechanisms by Which Nonnutritive Sweeteners May Affect Appetite,
Zachary T. Bloomgarden, MD
Food Intake and Weight Regulation
Dana Small, PhD
8:40am
Metabolic Effects of Non-Nutritive Sweeteners
9:10am
Sugar Sweetened Beverages and Obesity and Metabolic Disease
9:40am-9:55am
Q + A & Panel Discussion: ‘The Bitter Side of Sweet’
9:55am -10:20am
Refreshment Break At Exhibit Hall
M. Yanina Pepino, PhD
George Bray, MD
AWARD PRESENTATION By: Ralph DeFronzo, MD • Daniel Einhorn, MD
10:20am
KEYNOTE
SESSION XI
“Distinguished Leader in Insulin Resistance” Ele Ferrannini, MD
Insulin Resistance – The Old, the New, the Possible
Ele Ferrannini, MD
Metabolic Syndrome, The Liver
Chair: Paul Jellinger, MD
11:05am
Vitamin D and Metabolic Syndrome: Lessons Known so Far
11:35am
Managing NASH: Are We There Yet?
12:05pm-12:15pm
Q + A & Panel Discussion Clinical Implications
Arun Sanyal, MD
CONCURRENT SESSIONS CLINICAL WORKSHOPS
Lunch will be Served
12:20pm-1:10pm
Paul Jellinger, MD • Paul Rosenblit, MD
Philip Levy, MD • Andrew Drexler, MD
Alan Sinaiko, MD • Christian Mende, MD
Lipids
Diabetes
The Kidney & Hypertension
Carlos Bernal-Mizrachi, MD
SESSION XII
Chronic Heart Failure in Diabetes
Chair: Peter Grant, MD • Bart Staels, PhD
1:15pm
Pathophysiology of Heart Failure from Insulin Resistance to Diabetes
Peter Grant, MD
1:45pm
Mitochondrial Function in the Diabetic Heart
Bart Staels, PhD
2:05pm
Diagnosis and Management of Heart Failure in Diabetes
Mark Kearney, MD
2:35pm
Effects of Diabetes Therapies on CVD and Heart Failure
Vivian Fonseca, MD
3:05pm-3:15pm
Q + A & Panel Discussion Clinical Implications
3:15pm-3:30pm
Refreshment Break
Obesity Pre-Diabetes & Diabetes
Chair: Philip Levy, MD • Ele Ferrannini, MD
SESSION XIII
3:30pm
Is Obesity Pre-Diabetes and How Should It Be Managed?
4:00pm
What is New in the Pathophysiology and Treatment of Lipodystrophy and Obesity?
Christos Mantzoros, MD
4:30pm
Minimizing Hypoglycemia in Managing Diabetes: The Role of Incretins
George Grunberger, MD
5:00pm
Adjourn
Save the Date
13th WCIRDC will be held on November 19-21, 2015
Alan Garber, MD, PhD
Save the Date
FACULTY 2014
Yehuda Handelsman MD, FACP, FACE, FNLA
Chair & Program Director
Medical Director, Principal Investigator
Metabolic Institute of America
Tarzana, California
Muhammed Abdul-Ghani, MD, PhD
Associate Professor
Diabetes Division
University of Texas Health Science Center
San Antonio, Texas
Christie Ballantyne, MD
Professor of medicine
Baylor College of Medicine
Chief, Section of Atherosclerosis and Vascular
Medicine
Director, Center for Cardiovascular Disease
Prevention at Methodist DeBakey Heart Center
Co-director, Lipid Metabolism and Atherosclerosis
Clinic at the Methodist Hospital
Carlos Bernal-Mizrachi, MD
Associate Professor
Endocrinology, Metabolism, & Lipid Research
Washington University
St. Louis, Missouri
Zachary T. Bloomgarden, MD
Clinical Professor of Medicine
Mount Sinai School of Medicine
Assistant Attending in Medicine
Mount Sinai Hospital
Consultant in Endocrinology Lawrence Hospital
New York, New York
George Bray, MD
Boyd Professor
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Sonia Caprio, MD
Professor of Pediatric Endocrinology
Yale University School of Medicine
New Haven, Connecticut
Robert J. Chilton, DO, FACC
Professor of Medicine
Department of Medicine
Division of Cardiology
The University of Texas
Health Science Center
San Antonio, Texas
Rhoda H. Cobin, MD, MACE
Clinical Professor of Medicine
Mount Sinai School of Medicine
Past President, AACE & ACE
New York, New York
Suzanne Craft, PhD
Professor of Medicine
Co-Director, Roena B. Kulynych Center
Research Director, Sticht Center on Aging
Division of Geriatric Medicine
Department of Internal Medicine Wake Forest
School of Medicine
Winston-Salem, North Carolina
Samuel W. Cushman, PhD
Special Volunteer, Diabetes, Endocrinology,
& Obesity (Retired Chief, Experiment Diabetes,
Metabolism, and Nutrition Section)
NIDDK, NIH
Bethesda, Maryland
Henry N. Ginsberg, MD
Irving Professor of Medicine
Director, Irving Institute for
Clinical and Translational Research
Columbia University
New York City, New York
Ralph A. DeFronzo, MD
Professor of Medicine
Chief, Diabetes Division
University of Texas Health Science Center
Deputy Director Texas Diabetes Institute
San Antonio, Texas
Peter J. Grant, MD, FMedSci
Professor of Medicine and
Consultant Physician
Leeds Acute Trust LIGHT Laboratories
University of Leeds
Leeds, United Kingdom
Andrew J. Drexler, MD
Professor of Medicine
Co-Chief Division of
Clinical Endocrinology
Diabetes and Hypertension Director
Gonda (Goldschmied)
Diabetes Center
Los Angeles, California
George Grunberger, MD, FACP, FACE
Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and
Molecular Medicine & Genetics
Wayne State University School of Medicine
Oakland Universtiy Wm. Beaumont School of Medicine
Bloomfield Hills, Michigan
Daniel Einhorn, MD, FACP, FACE
Clinical Professor of Medicine
Diabetes & Endocrine Associates
Medical Director, Scripps Whittier
Institute for Diabetes
San Diego, California
Sergio Fazio, MD, PhD
William and Sonja Connor Chair of Preventive
Cardiology
Professor of Medicine
Director of Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, Oregon
Ele Ferrannini, MD
Professor of Internal Medicine
Department of Clinical & Experimental Medicine
University of Pisa
Pisa, Italy
Vivian Fonseca, MD
Chief, Endocrinology Section
Professor of Medicine and Pharmacology
Tullis-Tulane Alumni Chair in Diabetes
Tulane University School of Medicine
New Orleans, Louisiana
Alan J. Garber, MD, PhD, FACE
Professor, Departments of Medicine,
Biochemistry, & Molecular Biology
Baylor College of Medicine
Department of Medicine
Division of Diabetes, Endocrinology, &
Metabolism
Houston, Texas
W. Timothy Garvey, MD
Butterworth Professor & Chair
Department of Nutrition Sciences
GRECC Investigator and staff physician
Birmingham VA Medical Center
Director-UAB Diabetes Research/Training Center
Birmingham, Alabama
Lars Hansen, MD, PhD
Medical Director
Diabetes Development, Global Clinical Research
Bristol-Myers Squibb Company
Princeton, New Jersey
Lawrence Harkless, DPM
Founding Dean and Professor of Podiatric Medicine, Surgery,
and Biomechanics
College of Podiatric Medicine,
Western University of Health Sciences
Pomona, California
Robert R. Henry, MD
Professor of Medicine
Division of Endocrinology & Metabolism
University of California San Diego
Chief, Section of Diabetes, Endocrinology
& Metabolism
Director, Center for Metabolic Research
VA San Diego Healthcare System
San Diego, California
Marcus Hompesch, MD
President and CEO
Profil Institute for Clinical Research
Chula Vista, California
Allen Jacobs, DPM, FACFAS, FAPWH
Podiatric Medicine
Private Practice
Allen M. Jacobs DPM & Associates
St. Louis, Missouri
Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
University of Miami Miller School of Medicine
The Center for Diabetes & Endocrine Care
Past President, AACE & ACE
Hollywood, Florida
Peter Jones, MD
Associate Professor
Department of Medicine, Center for Cardiovascular Disease
Prevention
Baylor College of Medicine
Co-director of the Lipid Metabolism and Atherosclerosis Clinic
Medical Director, Weight Management Center
The Methodist Diabetes and Metabolism Institute
Houston, Texas
FACULTY 2014
Mark Kearney, MBChB, MRCP, MD
Professor of Cardiology
Head, Division of Cardiovascular & Diabetes Research
Lead for Heart Failure Services
University of Leeds
Leeds, United Kingdom
Samuel Klein, MD
Professor of Medicine &
Nutritional Science William H. Danforth
Director, Center for Human Nutrition
Chief, Division of Geriatrics & Nutritional Science
Washington University School of Medicine
St Louis, Missouri
Joshua W. Knowles, MD-PhD, FAHA, FACC
Instructor, Cardiovascular Medicine
Stanford University
Attending Physician, Stanford Center for Inherited
Cardiovascular Disease,
Familial Hypercholesterolemia (FH) Clinic
Stanford, California
Ronald M. Krauss, MD
Director, Atherosclerosis Research
Children’s Hospital Oakland
Senior Scientist, Genome Sciences Division
Lawrence Berkeley National Laboratory
University of California
Berkeley, California
Professor Andrew J.Krentz MD FRCP
Director of Cardiometabolic Research
Profil Institute for Clinical Research
Chula Vista, California
Derek LeRoith, MD, PhD
Director of Diabetes Research
CRIR, Rambam Health Care Campus
Haifa, Israel
Professor of Medicine
Division of Endocrinology
Icahn School of Medicine at Mt. Sinai
New York City, New York
Philip Levy, MD, MACE
Clinical Professor of Medicine
University of Arizona College of Medicine-Phoenix
Endocrinology Clinics, Ltd.
Past President ACE
Phoenix, Arizona
Alice Liu, MD
Instructor
Division of Endocrinology
Stanford University Medical Center
Stanford, California
Christos Mantzoros, MD DSc
Professor of Medicine, Harvard Medical School
Prof. of Environmental Health
Harvard School of Public Health
Chief of Endocrinology, Diabetes, & Metabolism
Editor-in-Chief, Metabolism, Clinical,
and Experimental
Boston, Massachusetts
Tracey L. McLaughlin, MD, MS
Assistant Professor of Medicine
Division of Endocrinology,
Gerontology, and Metabolism
Stanford Medical Center
Stanford, California
CW Mende, MD, FACP, FACN, FASN, FASH
Clinical Professor of Medicine
Specialist in Clinical Hypertension
University of California San Diego
La Jolla, California
John E. Nestler, MD
William Branch Porter
Professor of Medicine
Chair, Department of Internal Medicine
Virginia Commonwealth University
Richmond, Virginia
M. Yanina Pepino, PhD
Research Assistant Professor
Center for Human Nutrition
Washington University School of Medicine
St. Louis, Missouri
Jorge Plutzky, MD
Director, Vascular Disease
Prevention Program Cardiovascular Division
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
Olli Raitakari, MD, PhD
Professor, Cardiovascular Medicine
Director, Cardiovascular Centre of Applied &
Preventive Medicine
Head, Department of Clinical Physiology
University of Turku
Turku, Finland
Gerald M. Reaven, MD
Professor of Medicine (Active Emeritus)
Division of Cardiovascular Medicine
Stanford University School of Medicine
Stanford, California
Paul D. Rosenblit MD, PhD, FACE, FNLA
Clinical Professor of Medicine
Division of Endocrinology
Diabetes & Metabolism
Univerity of California Irvine
School of Medicine
Co-Director Diabetes
Outpatient Clinic Director
Diabetes Lipid Management &
Research Center
Irvine, California
Arun Sanyal, MBBS, MD, FACP
Professor of Internal Medicine
Chairman, Division of Gastroenterology,
Hepatology, and Nutrition
Virginia Commonwealth University
Health System
Richmond, Virginia
P.K. Shah, MD, FACC
Shapell and Webb Family Chair in Clinical Cardiology
Professor of Medicine
Director, Oppenheimer Atherosclerosis Research
Center, Atherosclerosis Prevention &
Treatment Center
Cedars Sinai Heart Institute
Los Angeles, California
Alan R. Sinaiko, MD
Professor, Department of Pediatrics
Division of Nephrology
University of Minnesota
Medical School Pediatric Nephrology
Minneapolis, Minnesota
Dana Small, PhD
Associate Professor of Psychiatry
The John B. Pierce Laboratory,
Yale School of Medicine
New Haven, Connecticut
University of Cologne
Köln, Germany
Bart Staels, PhD
Full Professor,
University of Lille Nord de France
Head of Inserm
Lille, France
Mellick T. Sykes, MD, MA (Anat.), FACS
Clinical Professor, Department of Surgery
University of Texas Health Science Center
Former Chief, Division of Vascular Surgery
Past President, Texas Surgical Society
Past President, Texas Society for Vascular and
Endovascular Surgery
San Antonio, Texas
Sotirios Tsimikas, MD, FACC, FAHA, FSCAI
Director of Vascular Medicine
Professor of Medicine,
US San Diego Health Center
Sulpizio Cardiovascular Center
La Jolla, California
Accreditation Information
You can earn up to 27.5 credits
Physicians This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council
for Continuing Medical Education through the joint sponsorship of PESI, Inc. and the Foundation (MEEF). PESI, Inc. is accredited by the
ACCME to provide continuing medical education for physicians.
AMA PRA Designation Statement The PESI, Inc. designated this live activity for a maximum of approximately 27.5 hours should
only claim credit commensurate with the extent of their participation in the activity.
Family Physicians American Academy of Family Physicians This Live activity, 12th Annual World Congress on Insulin Resistance,
Diabetes & Cardiovascular Disease (WCIRDC), with a beginning date of 11/20/14, has been reviewed and is acceptable for up to 25.5
Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the
extent of their participation in the activity.
International CME International Physicians are formally eligible for AMA PRA Category 1 Credit™.
Physician Assistants AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit
from organizations accredited by ACCME.
Pharmacists Accreditation Statement The Minnesota Pharmacists Association is accredited by the Accreditation
Council for Pharmacy Education (ACPE) as a provider of continuing education. Successful completion of the 2014 12th
WCIRDC qualified for a maximum of approximately 27.5 contact hours.
Nurses This nurse activity has been submitted for approval to the Wisconsin Nurses Association, an accredited approver by the
American Nurses Credentialing Center's Commission on Accreditation.
CA Nurses Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated
the 2014 12th WCIRDC for approximately 27.5 contact hours.
Registered Dieticians This program has been submitted for approval by the Commission on Dietetic Registration.
Satisfactory Completion for Credits All attendees must have completed and turned in a course attendance/evaluation form prior
to leaving the conference. Each session claimed for credit must be attended in its entirety.
Program Committee
Yehuda Handelsman, MD • Nikolaus Marx, MD • Sonia Caprio, MD • Peter Grant, MD • Tracey McLaughlin, MD, MS
W. Timothy Garvey, MD • Samuel Cushman, PhD • Bart Staels, PhD • Zach Bloomgarden, MD • Samuel Klein, MD • Maurice T. Zagha, MD
Robert Chilton, DO, FACC Renee S. Asp, BS • Ronald M. Krauss, MD
• Ralph A. DeFronzo, MD • Jane Seley, DNP, MSN, MPH, DC-ADM, CDE, CDTC
Special Thanks Gerald Reaven, MD
The International Committee for Insulin Resistance Gratefully Acknowledges the Educational Support of
Premier Educator
Leader Educator
Major Educator
Educator
Associate Educator
AstraZeneca
Amgen
Novo Nordisk • Merck
Takeda • Vivus
Salix
Lilly
Accommodations
The 12th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular (WCIRDC) will be held at the prestigious Hilton Universal
Hotel. The majestic Hilton Hotel is situated on a hill high above the Los Angeles Entertainment District, at the very entrance to Universal Studios
Hollywood and CityWalk. Every room of the hotel offers a commanding view of the Hollywood Hills, San Fernando Valley, and Universal
Studios Hollywood. The hotel is six miles from the Burbank Airport, and seventeen miles from the Los Angeles International Airport.
Hilton Universal City Hotel
555 Universal Hollywood Dr. Universal City, CA 91608
Call 818.506.2500 or visit www.wcir.org/hotel.php
To receive the special group rate of $169/night for conference participants and their guests.
and reference the group name “WCIRDC”
Rooms will be available on a first-come basis, and will be available until all are filled. Group room rates will be available three (3) days prior
to and three (3) days after the event dates. If you need special accommodations or if you have any questions about access to any of our
activities, please contact the meeting organizers at: (818) 342-1889 or [email protected]
Los Angeles Attractions
Just minutes from popular attractions • Universal Studios • Hollywood Universal • CityWalk • Getty Center Museum • Rodeo Drive/Beverly
Hills • Hollywood/Walk of Fame • Melrose Avenue • Hollywood Bowl • Chinese Theater • Los Angeles Zoo • Griffith Park Observatory
• Staples Center/Downtown • Chinatown and more...
Corporate Opportunities & Exhibit Space are still available!
• Don't miss the opportunity to be a part of the 12th WCIRDC
• Showcase your products, services and technologies!
• Reach out to the most influential leaders and decision-makers in the field
• Meet with globally-recognized medical leaders, clinicians and scientists, who
present and share their knowledge.
We will dedicate an area, separate from the educational program, where your
company will be able to exhibit products, equipment, and services
[email protected] • 818.342.1889 • www.WCIR.org
The International Committee for Insulin Resistance Gratefully Acknowledges the Corporate Support of
Sapphire Level
Amgen Cardiovascular
Topaz Level
Boehringer Ingelheim • AstraZeneca
Janssen
4
EASY WAYS TO REGISTER
1 Online: www.WCIR.org
4 Mail Registration Form with Payment:
2 Tel: 818.342.1889
3 Fax: 818.342.1538
Complete and send to:
Metabolic Endocrine Education Foundation (MEEF)
18372 Clark Street, # 212 Tarzana, CA 91356
REGISTRATION FEE INCLUDES CME credit, course materials, workshops, breakfast, refreshment breaks and welcome reception
10/20/14
11/20/14
On-Site
Attendee
$480
$525
$625
Member of Participating Organization
$380
$425
$525
Fellow/Resident
Student Medical Student Only
$195
$250
$300
$95
$95
FREE with student ID
$185
$210
$235
Daily
Fee will be refunded onsite
when you present Student ID.
11/20 11/21 11/22
Indicate Participating Organization name: (see back for a full list) ___________________________________________________________________________
REGISTRANT CONTACT INFORMATION This will be used for your badge, please print clearly
First Name ___________________________ Last Name_____________________________ Degree ______________________
Email (please print clearly) ________________________________________________________________________________
Company/Organization __________________________________________________________________________________
_________________________________________________Specialty __________________________________________
Address ____________________________________________________________________________________________
City ____________________________________________ State ______________________ Zip Code __________________
Phone ___________________________Fax ____________________________ Country _____________________________
MEET THE EXPERT Please select one
THURSDAY, November 20, 2014 at 11:45am Lunch will be served
□ Gerald Reaven, MD - Insulin Resistance □ Ralph De Fronzo, MD - Insulin Resistance & DM □ John Nestler, MD - PCOS
□ Andrew Krentz, MD / Marcus Hompesch, MD -Measuring Insulin Action in Diabetes Drug Development □ Not Interested
CONCURRENT SESSIONS Please select one
SATURDAY, November 22, 2014 at 12:20pm
□ Lipids □ Diabetes □ Kidney & HTN □ Not Interested
These programs are FREE for attendees of the 12th WCIRDC – Pre-registration is a MUST!
PAYMENT Credit card will be charged immediately. Confirmation will be sent via email after receiving registration form
Check: Make check payable to MEEF (Metabolic Endocrine Education Foundation)
□
Visa
□
MasterCard
□
Cancellation Policy: A $75 cancellation fee will be charged for
cancellation between August 18th and October 20th. After
10/20/2014 there will be NO REFUND. We encourage
participation by all individuals. If you have a disability, please
notify us in writing of any special requirements to help us serve
you better.
American Express
Credit Card # ____________________________________________________ Exp. date :_________________________________________________
Name: ________________________________________________________ Signature: ________________________________________________
For Additional Information on SUPPORT • REGISTRATION • ACCOMMODATION • EXHIBIT
Tel: 818 342 1889 • Fax: 818 342 1538 • [email protected]
Metabolic Endocrine Education Foundation
18372 Clark Street # 212 Tarzana, California 91356
SAVE THE DATE
13th WCIRDC
November 19-21, 2015
Los Angeles, California
CO – SPONSORS
& PARTICIPATING
ORGANIZATIONS
12th WCIRDC
November 20-22, 2014
• American Association of Clinical Endocrinologists
• American College of Endocrinology
American Board of Obesity Medicine
American Association for the Study of Liver Diseases (AASLD)
American Diabetes Association – Los Angeles
Androgen Excess Society
American Society of Endocrine Physician Assistants
The Lawson Wilkins Pediatric Endocrine Society
• National Lipid Association
Israel Endocrine Society
The European Association for the study of the liver (EASL)
American Gastroenterological Association
All Members of Participating Organizations
Qualify for a Discount on Registration
Hilton Universal City - Los Angeles, CA
American Academy of Pediatrics
American College of Nutrition
American Heart Association Council of Nutrition
American Society for Clinical Nutrition (ASCN)
American Society for Preventive Oncology (ASPO)
Canadian Association of Gastroenterology
Chinese Association for Clinical Endocrinologists
European Association for the Study of Diabetes (EASD)
European Society of Cardiology (ESC)
FH Foundation
International Associations for the Study of Obesity
International Society of Diabetes and Vascular Disease
International Academy of Cardiology
Joslin Diabetes Center
New Cardiovascular Horizons (NCVH)
For Additional Information on SUPPORT • REGISTRATION • ACCOMMODATION • EXHIBIT
Tel: 818 342 1889 • Fax: 818 342 1538 • [email protected]
www.WCIR.org
`